Target intelligence / Profile preview

Denticleless E3 ubiquitin protein ligase homolog (DTL)

Target
DTL
Molecular classification
E3 ubiquitin ligase, Enzyme, DDB1- and CUL4-associated factor, WD40 repeat-containing protein
01

Overview

Denticleless E3 ubiquitin protein ligase homolog (DTL), also widely known as CDT2, is a critical substrate-recruiting component of the CRL4 (Cullin 4-DDB1) E3 ubiquitin ligase complex. It plays an essential role in maintaining genomic integrity, regulating DNA replication, and coordinating cell cycle progression. By binding to proliferating cell nuclear antigen (PCNA) on chromatin, DTL targets key regulatory proteins—such as the replication licensing factor CDT1, the cyclin-dependent kinase inhibitor p21, and the histone methyltransferase SET8—for polyubiquitination and subsequent proteasomal degradation during the S phase and following DNA damage. This tightly regulated proteolysis prevents unscheduled origin firing and DNA re-replication, thereby safeguarding the genome. DTL is frequently overexpressed in various human malignancies, including gastric, breast, bladder, and hepatocellular cancers, where its upregulation promotes uncontrolled cell proliferation, chemoresistance, and poor clinical outcomes. Additionally, DTL has been implicated in Alzheimer's disease through aberrant neuronal cell cycle reentry, and in cardiovascular disease via the degradation of the cholesterol transporter ABCA1. While direct small-molecule inhibitors of DTL are not yet clinically established, its activity can be indirectly modulated by neddylation inhibitors like pevonedistat (MLN4924) or COP9 signalosome inhibitors, and its expression is downregulated by drugs such as colchicine.

Other names
CDT2DCAF2L2DTLRAMPDenticleless protein homologCdc10-dependent transcript 2DDB1- and CUL4-associated factor 2Lethal(2) denticleless protein homologRetinoic acid-regulated nuclear matrix-associated protein
02

Mechanism of action

Indirect inhibition of CRL4-Cdt2 via inhibition of NEDD8-activating enzyme (NAE) to block cullin neddylation, indirect inhibition via COP9 signalosome (CSN) inhibition, or downregulation of DTL expression and disruption of its interaction with substrates.

03

Biological functions

Protein ubiquitinationCell cycleDNA replicationDNA damage responseTranslesion DNA synthesisApoptosisCell proliferationMitotic G2 DNA damage checkpoint signaling
04

Disease associations

CancerNeurodegenerative diseaseCardiovascular disease
05

Safety considerations

Genomic instabilityDNA re-replicationMitotic catastropheEarly embryonic lethalitySystemic toxicity
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

DTL overexpressionCDT1 accumulationp21 accumulationSET8 accumulation

Beyond the preview

Go deeper on Denticleless E3 ubiquitin protein ligase homolog (DTL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Denticleless E3 ubiquitin protein ligase homolog (DTL).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call